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Aims: Higher mean platelet volume (MPV) in diabetic patients has been considered as an emerging risk factor for diabetes 
related micro- and macrovascular complications. Human paraoxonase 1/arylesterase (PON1), which has antioxidant and 
antiatherogenic properties, is documented in high oxidative stress conditions like uncontrolled diabetes. The present study 
aimed to evaluate the relationship between mean platelet volume (MPV) and paraoxonase-1 (PON-1) activity, brachial artery 
diameter (BAd) and intima media thickness (BA-IMT), in diabetic patients with regard to obesity and diabetic complications.
Methods: Two-hundred and one diabetic patients (mean age: 52.4  ±  13.4  years, 73.6% females) were grouped according to 
obesity and diabetic complications (microvascular and macrovascular). Data on demographics, anthropometrics, diabetic 
complications, MPV levels, BAd and BA-IMT, and serum paraoxonase and arylesterase activities were recorded. The correlation of 
MPV values to paraoxonase and arylesterase activities, BAd and BA-IMT was evaluated.
Results: Paraoxonase and arylesterase values were 119.8  ±  37.5 U/L and 149.0  ±  39.9 U/L, respectively, with no significant 
difference in respect of obesity and macrovascular complications. Significantly lower values for paraoxonase (107.5 ± 30.7 vs. 
123.9 ± 38.8 U/L, p = 0.007) and arylesterase (132.1 ± 30.2 vs. 154.7 ± 41.2, U/L, p = 0.001) were noted in patients with microvascular 
complications. MPV values were 9.10 ± 0.87 fL, with no significant difference across the groups and no significant correlation with 
other parameters.
Conclusion: In conclusion, PON-1 activity is more significantly decreased in diabetic patients with microvascular than 
macrovascular complications with no effects on MPV values. On the other hand, no relationship was found between thrombogenic 
activity and PON-1 activity, BAd and BA-IMT regardless of obesity and diabetic complications.
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Introduction
Type 2 diabetes mellitus (T2DM) is a component of metabolic 
syndrome associated with dyslipidaemia, hypertension, impaired 
fibrinolysis, and increased pro-coagulation factors.1–3 It ranks as 
the major risk factor for the development of coronary artery 
disease (CAD)4,5 due to the central role of oxidative stress in the 
pathology of diabetes mellitus.6,7
In addition to cardiovascular manifestations, diabetes mellitus 
has been associated with an increased risk of micro- and macro-
vascular complications, which are a major cause of morbidity 
and mortality,8 as oxidative stress is considered a link between 
diabetes mellitus and related complications.9,10
Human paraoxonase 1/arylesterase (PON1) is a calcium-
dependent ester hydrolase with paraoxonase, arylesterase and 
dyazoxonase activities, and antioxidant and anti-atherogenic 
properties11–14 shown to be inversely related to the risk of CVD.15 
Accordingly, a decrease in PON1 activity has been documented 
in states of high oxidative stress like metabolic syndrome, 
obesity, uncontrolled diabetes, and dyslipidaemia.16
It is suggested that decreased PON1 activity in patients with type 2 
diabetes mellitus may lead to accelerated atherosclerosis, which 
causes increased mortality due to CAD.17–19
The early stages of atherosclerosis consist of functional 
impairment of endothelial surface with consequent impairment 
of arterial vasodilation capacity and thickening of the intima-
media space.20,21 In addition to carotid intima-media thickness 
(IMT), which was considered a validated parameter in detecting 
subclinical atherosclerosis and the severity of coronary 
atherosclerosis,20,21 it was shown that brachial artery IMT (BA-
IMT) correlated to carotid IMT. Consequently, it may serve as a 
marker of cardiovascular risk, and as initial steps of the 
atherosclerotic process.22
Mean platelet volume (MPV) is a parameter of platelet size, which 
is easily determined on routine automated haemogram and is 
routinely available at a relatively low cost.23 Higher MPV values, a 
marker of increased thrombogenicity and atherosclerosis, have 
been reported in patients with acute myocardial infarction, 
stroke, diabetes mellitus, congestive heart failure and in 
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hypertensive patients with evidence of target organ damage.24–26 
The volume of thrombocytes is increased with increased 
thrombocyte activation. It is known that large platelets have 
more thrombotic potential than smaller ones, they have more 
intense granules and are more effective metabolically and 
enzymatically.27 Moreover, cytokines, such as interleukin-3 or 
interleukin-6, influence megakaryocyte ploidy and can lead to 
the production of more reactive, larger platelets at the level of 
progenitor cells such as megakaryocytes.28 Altered platelet 
morphology, function and increased levels of MPV have been 
reported to lead to the synthesis of more thromboxane1,29,30 in 
diabetic patients. This condition is currently considered an 
emerging risk factor for atherothrombosis31–33 and is an 
accelerating factor in the development of micro- and 
macrovascular complications of diabetes.29,30
The present study was hence designed to evaluate the relation of 
mean platelet volume (MPV) levels with serum PON-1 activity and 
brachial artery diameter (BAd) and BA-IMT in diabetic patients 
with respect to obesity and diabetic complications.
Materials and methods
A total of 201 diabetic patients (mean age: 52.4  ±  13.4  years, 
73.6% were females) were included in this study, and grouped 
with respect to obesity (obese: BMI ≥ 30 kg/m2; n = 89 and non-
obese: BMI  ≤  29.99  kg/m2; n = 112) and diabetic complications 
(with [n = 50] or without [n = 150] microvascular complications 
and with [n = 91] or without [n = 108] macrovascular 
complications). Outpatients aged between 18 and 75 years, who 
were diagnosed and treated for T2DM (fasting blood 
glucose  >  126  mg/dl or blood glucose level of  >  200  mg/dl at 
random measurements or haemoglobin A1C  >  6.5%), and who 
signed informed consents were included in the study. Patients 
with psychiatric disorders, cancer history, chronic renal failure, 
thrombocytopenia, myeloproliferative disease, chronic liver 
disease or hepatic failure, coronary artery disease or history of 
acute myocardial infarction were excluded from the study.
Written informed consent was obtained from each subject 
following a detailed explanation of the objectives and protocol of 
the study, which was conducted in accordance with the ethical 
principles stated in the Declaration of Helsinki and approved by 
the institutional ethics committee.
Assessments
Data on demographic (age, gender) and lifestyle (smoking status, 
alcohol consumption, regular physical exercise) characteristics of 
patients, anthropometric measurements (height, weight, body 
mass index [BMI]), diabetes-related microvascular (neuropathy, 
retinopathy and nephropathy) and macrovascular (hypertension, 
CAD, past history of coronary artery bypass grafting [CABG], 
peripheral artery disease [PAD], stroke and past history of myocardial 
infarction [MI]) complications, MPV levels (fL), BAd and BA-IMT and 
serum paraoxonase and arylesterase activities were recorded. 
Correlation of MPV values to paraoxonase and arylesterase activities, 
as well as to BAd and BA-IMT, was evaluated in the study groups.
Mean platelet volume (MPV)
MPV, as a component of complete blood count test, was 
determined in a Coulter LH 750 auto analyser (Beckman Coulter, 
CA, USA). Blood samples collected in tubes with EDTA were 
transferred to the biochemistry laboratory within 30 minutes, and 
laboratory analysis was performed immediately so that time to 
analysis was not a confounding factor for MPV results. The expected 
normal range for Beckman Coulter LH 750 device was 6.9–16 fL.
Measurement of paraoxonase and arylesterase 
activities
Venous blood samples were collected in tubes from the antecubital 
vein, following an overnight fasting. The tubes were centrifuged at 
2000 g (10 minutes) to remove plasma and serum. The plasma and 
serum samples were kept at –80°C until analysis of PON1 activity.
Paraoxonase and arylesterase activities were determined using a 
novel automated measurement method developed by Erel 
(Relassay®, Turkey). Briefly, the rate of paraoxon hydrolysis was 
measured by increased absorbance at 412 nm at 25°C. The PON 
activity is expressed as U/L serum. The coefficient of variation (CV) 
for individual samples was 1.8%. Arylesterase activity was 
measured spectrophotometrically using phenyl acetate. The 
reaction was initiated by the addition of the serum; the increase in 
absorbance was read at 270 nm. Enzymatic activity was calculated 
from the molar absorptivity coefficient of the produced phenol. 
One unit of arylesterase activity was defined as 1  μmol phenol 
generated/minute under defined assay conditions and expressed 
as U/L serum. The CV for individual serum samples was 3.3%.
Measurement of brachial artery diameter (BAd) and 
intima media thickness (BA-IMT)
Ultrasonography (US) examinations, IMT and brachial artery 
diameter measurements were performed by the same radiologist. 
After a five-minute rest in the supine position the brachial artery 
was examined in a longitudinal plane between the antecubital 
fossa and axilla by continuous grey-scale imaging with a linear, 
high resolution Dynamic Micro Slice (7–18  MHz) transducer. US 
examinations were performed by Toshiba Aplio 500 (Toshiba 
Medical Systems Corporation, Nasu, Japan). Measurement of IMT 
in the brachial artery was performed at the proper site, where IMT 
was considered the thickest, and where the clearest B mode image 
of the anterior and posterior intimal interfaces between the lumen 
and vessel wall was obtained above antecubital fossa. IMT was 
measured three times and the brachial IMT was defined as the 
mean of these three measurements. On the same image where the 
IMT was measured, the distance between the two intimal interfaces 
was measured and defined as the diameter of the brachial artery.
Statistical analysis
Statistical analysis was made using the MedCalc Statistical 
Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2013). The Mann–Whitney U test was 
used to analyse independent non-parametric variables, while the 
Pearson and Spearman correlation analyses were performed to 
determine correlations between parametric and non-parametric 
variables, respectively. Data were expressed as ‘mean ± standard 
deviation (SD)’, minimum–maximum and percentage (%) where 
appropriate. P < 0.05 was considered statistically significant.
Results
Patient characteristics
Overall, obesity was determined in 44.3% of the patients; at least 
one diabetic microvascular complication was evident in 50 
(75.1%) patients, including neuropathy (19.4%), retinopathy 
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(12.9%), and nephropathy (8.5%). At least one diabetic 
macrovascular complication was evident in 91 (45.5%) patients, 
including hypertension (42.8%), CAD (6.5%), past history of CABG 
(4.0%), PAD (1.0%), stroke (0.5%) and past history of MI (0.5%). 
Active smokers made up 13.9% of the study population, while 
regular alcohol consumption and physical activity were noted in 
10% and 28.4% of patients, respectively (Table 1).
HbA1c was 7.4 ± 1.9% and blood glucose was 148.2 ± 61.6 mg/dL 
in the overall study population.
MPV, paraoxonase and arylesterase levels in the 
study groups
Paraoxonase and arylesterase values were 119.8 ± 37.5 U/L and 
149.0 ± 39.9 U/L, respectively in the overall population, with no 
significant difference with respect to obesity and macrovascular 
diabetic complications, whereas significantly lower values for 
paraoxonase (107.5  ±  30.7 vs. 123.9  ±  38.8 U/L, p = 0.007) and 
arylesterase (132.1  ±  30.2 vs. 154.7  ±  41.2 U/L, p = 0.001) were 
noted in patients with than in those without diabetic 
microvascular complications (Table 2).
Table 1: Patient characteristics (n = 201)
Factor No. (%)
Age (years), mean ± SD 52.4 ± 13.4
 ≤ 50 years, n (%) 85 (42.5)
 > 50 years, n (%) 115 (57.5)
Gender, n (%)
 Female 148 (73.6)
 Male 53 (26.4)
Anthropometrics, mean ± SD
 Height (cm) 164.1 ± 7.5
 Weight (kg) 79.9 ± 14.9
 BMI (kg/m2) 29.8 ± 6.1
  Obese (BMI ≥ 30 kg/m2), n (%) 89 (44.3)
  Non-obese (BMI ≤ 29.99 kg/m2), n (%) 112 (55.7)
Diabetes-related complications n (%)
 At least one1 microvascular complication 50 (75.1)
  Retinopathy 26 (12.9)
  Neuropathy 39 (19.4)
  Nephropathy 17 (8.5)
 At least one macrovascular complication 91 (45.5)
  Hypertension 86 (42.8)
  Coronary artery disease 13 (6.5)
  Past history of CABG 8 (4.0)
  Peripheral artery disease 2 (1.0)
  Stroke 1 (0.5)
  Past history of MI 1(0.5)
Smoking status, n (%)
 Active smoker 28 (13.9)
 Non-smoker 169 (84.1)
 Ex-smoker 4 (2.0)
Alcohol consumption, n (%)
 Regular 10 (10.0)
 None 179 (89.1)
 Seldom 2 (1.0)
Physical exercise, n (%)
 Regular 57 (28.4)
 None 143 (71.1)
 Seldom 1 (0.5)
Family history for diabetes mellitus 96 (47.8)
Hypoglycaemia 15 (7.5)
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values was observed in obese vs. non-obese patients, or in 
patients with vs. those without diabetic complications. No 
significant correlation was found between MPV values and PON-1 
activity or BAd or BA-IMT in our study population, regardless of 
the obesity or diabetic complication status.
Lower PON1 activity was also shown in diabetic patients with 
complications,34 including macrovascular35,36 and microvascular37 
complications, and especially in those with neuropathy and 
nephropathy, leading to a higher risk for atherosclerosis.16
No difference was noted with regard to macrovascular 
complications. However, significantly lower paraoxonase and 
arylesterase activities in our diabetic patients with microvascular 
complications compared with those without microvascular 
complications were found to be consistent with the more 
pronounced decrease in PON1 activity reported in patients with, 
than in those without diabetic nephropathy, when compared 
with controls.37–41 This relationship was also reported in patients 
with, than in those without diabetic retinopathy39,42,43 as well as in 
the data on the lowest levels of paraoxonase specific activity in 
patients with peripheral neuropathy.42 In this regard, our findings 
suggested that decreased PON1 activity in patients with type 2 
MPV values were 9.10 ± 0.87 fL in the overall population, with no 
significant difference in respect of obesity and diabetic 
complications (Table 2).
Correlation of MPV values to paraoxonase and 
arylesterase activities in the study groups
No significant correlation of MPV values to paraoxonase and 
arylesterase activities was noted in the overall study population 
as well as in study groups of obese vs. non-obese patients, and in 
patients with vs. those without diabetic complications (Table 3).
Correlation of MPV values to BAd and BA-IMT in the 
study groups
No significant correlation of MPV values to BAd and BA-IMT was 
noted in the overall study population, or in study groups of obese 
vs. non-obese patients and patients with vs. without diabetic 
complications (Table 4).
Discussion
The study results revealed significantly lower PON-1 activity in 
diabetic patients with microvascular complications than in those 
without microvascular complications, while no difference in MPV 
Table 2: MPV, paraoxonase and arylesterase levels in study groups
1Mann–Whitney U test.
Factor MPV (fL) Paraoxonase (U/L) Arylesterase (U/L)
Overall (n = 201) Mean ± SD 9.10 ± 0.87 119.8 ± 37.5 149.0 ± 39.9
Median (min–max) 9 (7.3–12.2) 116.25 (46.6–262.0) 141.20 (90.7–279.2)
Obesity
Present (n = 89)
Mean ± SD 9.0 ± 0.9 119.5 ± 35.6 150.4 ± 39.0
Median (min–max) 8.9 (7.3–11.8) 121 (55.8–195.5) 144 (90.7–229.8)
Absent (n = 112)
Mean ± SD 9.1 ± 0.8 120.0 ± 39.1 147.9 ± 40.7
Median (min–max) 9.2 (7.4–12.2) 112.3 (46.6–262) 141.2 (94.6–279.2)
p-value1 0.282 0.879 0.464
Microvascular complications
Present (n = 50)
Mean ± SD 9.1 ± 0.9 107.5 ± 30.7 132.1 ± 30.2
Median (min–max) 9 (7.3–11.8) 98.7 (63.1–177.2) 123 (90.8–201.3)
Absent (n = 150)
Mean ± SD 9.1 ± 0.9 123.9 ± 38.8 154.7 ± 41.2
Median (min–max) 9.1 (7.3–12.2) 121.4 (46.6–262) 153.9 (90.7–279.2)
p-value1 0.792 0.007 0.001
Macrovascular complications
Present (n = 91)
Mean ± SD 9.0 ± 0.9 120.6 ± 36.1 147.5 ± 36.6
Median (min–max) 9 (7.3–12.2) 117.2 (55.8–213.8) 140.5 (95.8–250.4)
Absent (n = 108)
Mean ± SD 9.2 ± 0.8 119.6 ± 38.7 150.8 ± 42.3
Median (min–max) 9 (7.3–11.6) 116.4 (46.6–262) 148.1 (90.7–279.2)
p-value1 0.169 0.729 0.799
Table 3: Correlation of mean platelet volume (MPV) values to paraoxonase and arylesterase activities in study groups
Note: Spearman correlation analysis r: correlation coefficient.
Factor Paraoxonase Arylesterase
r p r p
MPV Overall (n = 201) −0.002 0.983 −0.040 0.577
Obesity Present (n = 89) 0.071 0.531 0.049 0.665
 Absent (n = 112) −0.033 0.747 −0.067 0.515
Microvascular complications Present (n = 50) −0.172 0.233 −0.159 0.270
 Absent (n = 150) 0.049 0.548 −0.003 0.974
Macrovascular complications Present (n = 91) −0.145 0.189 −0.072 0.514
 Absent (n = 108) 0.111 0.251 0.049 0.617
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inducing nonenzymatic glycation of proteins on the platelet 
surface, through the osmotic effect of glucose and activation of 
protein kinase C. Such glycation decreases membrane fluidity 
and increases the propensity of platelets to activate.54–57
Higher levels for MPV were shown in diabetic patients than in the 
control group, and also in diabetic patients with, than in those 
without retinopathy, along with a positive correlation with FBG and 
HbA1c levels, in another study from Turkey.62 Moreover, MPV has 
been suggested to be a simple and cost-effective tool to monitor 
the progression and control of T2DM, and a useful prognostic 
marker of cardiovascular complications in patients with T2DM.3,60
Notably, a difference between platelet volume indices in terms of 
their association with macrovascular and peripheral neuropathy 
complications was also reported in a previous study on type 2 
diabetic patients, which indicated that both MPV and platelet 
distribution width (PDW) were significantly associated with vibration 
perception threshold (VPT), while only PDW, but not MPV, was 
significantly associated with carotid IMT in a multivariate analysis.63
In this regard, and although the lack of a control group limits the 
interpretation of our findings in relation to the above findings, 
MPV values were within the normal non-diabetic range in our 
diabetic patients with no difference in MPV values, with regard to 
presence of obesity or diabetic complications. Accordingly, aside 
from the lack of an increased platelet activity, which is one of the 
mechanisms deemed responsible for the pathogenesis of 
atherosclerosis,24–26 no correlation of MPV levels to BAd and BA-
IMT was noted in our study population.
In addition, on the basis of mean HbA1c (7.4%) and blood glucose 
(148.2  mg/dL) in our study population, it should be noted that 
platelet hyper-reactivity and increased baseline activation in 
patients with diabetes mellitus has been considered to be 
multifactorial and related to certain biochemical factors including 
hyperglycaemia, insulin resistance and hyperlipidaemia.56 Several 
limitations to this study should be considered. First, the cross-
sectional nature of the study and lack of a non-diabetic control 
group along with the relatively small sample size precluded the 
possibility of drawing extensive causal conclusions and generalising 
our findings to the overall diabetic population. Second, no data are 
available considering surrogate serum biomarkers of oxidative 
stress alterations, which could have impacts on PON1 protein 
diabetes mellitus was probably playing a role in the development 
of diabetic vascular complications.38–41
Following the first data on decreased PON1 paraoxonase activity 
and increased lipid peroxidation levels in isolated HDL from 
obese adult patients,44 a decreased serum PON1 arylesterase 
activity was consistently reported in obese adults.45,46 Although 
data on PON1 paraoxonase activity in obesity revealed 
inconsistent findings with decrease in activity as shown in some 
studies,47,48 similar to our study no significant change was reported 
in the others.49–51
Enhanced platelet activity has been documented,3,54 in relation to 
the fact that abnormal platelet–endothelial interaction is an 
essential pathogenic mechanism in the development of 
atherosclerosis.52,53 Larger platelets are younger, more reactive, 
contain denser granules, and secrete more serotonin and 
β-thromboglobulin. They have been reported to produce more 
thromboxane A2 than smaller platelets. All these can produce a 
pro-coagulant effect and cause thrombotic vascular 
complications. This suggests a relationship between platelet 
function, especially with MPV and diabetic vascular complications, 
thus indicating changes in MPV and reflecting the state of 
thrombogenesis. High MPV has currently therefore emerged as a 
new risk factor for the vascular complications of DM.54–56
Significantly higher values for MPV in diabetic patients as opposed 
to non-diabetic subjects have consistently been reported in 
previous studies, with regard to an increased thrombotic 
state.3,29,30,57–59 Data from different cohorts of type 2 diabetes 
mellitus patients in Turkey revealed significantly higher values for 
MPV in diabetics compared with age- and sex-matched non-
diabetic healthy controls,29,60 and also in diabetics and subjects 
with impaired fasting glucose compared with the non-diabetic 
group, along with a positive correlation of MPV with HbA1c and 
fasting blood glucose (FBG) levels.60
Similarly, in another study from Turkey, MPV levels were reported 
to be significantly higher in type 2 diabetic patients with HbA1c 
levels > 7% than in patients with HbA1c levels ≤ 7% and in non-
diabetics,3 which is consistent with the statement that glycaemic 
control reduces MPV levels and hence the possible role of 
platelets in cardiovascular events observed in type 2 diabetic 
patients.61 Hyperglycaemia can increase platelet reactivity by 
Table 4: Correlation of mean platelet volume (MPV) values to brachial artery diameter and intima media thickness (IMT) in study groups
Note: Spearman correlation analysis. r: correlation coefficient.
Factor MPV values
Obesity Microvascular complications Macrovascular complications
(+) (−) (+) (−) (+) (−)
Brachial artery IMT
Right r −0.209 0.140 −0.011 −0.061 0.046 −0.063
p 0.150 0.318 0.952 0.610 0.771 0.634
Left r −0.232 0.114 −0.077 −0.064 0.012 −0.010
p 0.108 0.415 0.687 0.590 0.938 0.943
Brachial artery diameter
Right r −0.131 −0.042 −0.204 −0.084 −0.274 0.109
p 0.369 0.764 0.280 0.484 0.079 0.412
Left r −0.094 −0.068 −0.361 0.008 −0.205 0.054
p 0.522 0.627 0.050 0.944 0.193 0.685
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inducing nonenzymatic glycation of proteins on the platelet 
surface, through the osmotic effect of glucose and activation of 
protein kinase C. Such glycation decreases membrane fluidity 
and increases the propensity of platelets to activate.54–57
Higher levels for MPV were shown in diabetic patients than in the 
control group, and also in diabetic patients with, than in those 
without retinopathy, along with a positive correlation with FBG and 
HbA1c levels, in another study from Turkey.62 Moreover, MPV has 
been suggested to be a simple and cost-effective tool to monitor 
the progression and control of T2DM, and a useful prognostic 
marker of cardiovascular complications in patients with T2DM.3,60
Notably, a difference between platelet volume indices in terms of 
their association with macrovascular and peripheral neuropathy 
complications was also reported in a previous study on type 2 
diabetic patients, which indicated that both MPV and platelet 
distribution width (PDW) were significantly associated with vibration 
perception threshold (VPT), while only PDW, but not MPV, was 
significantly associated with carotid IMT in a multivariate analysis.63
In this regard, and although the lack of a control group limits the 
interpretation of our findings in relation to the above findings, 
MPV values were within the normal non-diabetic range in our 
diabetic patients with no difference in MPV values, with regard to 
presence of obesity or diabetic complications. Accordingly, aside 
from the lack of an increased platelet activity, which is one of the 
mechanisms deemed responsible for the pathogenesis of 
atherosclerosis,24–26 no correlation of MPV levels to BAd and BA-
IMT was noted in our study population.
In addition, on the basis of mean HbA1c (7.4%) and blood glucose 
(148.2  mg/dL) in our study population, it should be noted that 
platelet hyper-reactivity and increased baseline activation in 
patients with diabetes mellitus has been considered to be 
multifactorial and related to certain biochemical factors including 
hyperglycaemia, insulin resistance and hyperlipidaemia.56 Several 
limitations to this study should be considered. First, the cross-
sectional nature of the study and lack of a non-diabetic control 
group along with the relatively small sample size precluded the 
possibility of drawing extensive causal conclusions and generalising 
our findings to the overall diabetic population. Second, no data are 
available considering surrogate serum biomarkers of oxidative 
stress alterations, which could have impacts on PON1 protein 
diabetes mellitus was probably playing a role in the development 
of diabetic vascular complications.38–41
Following the first data on decreased PON1 paraoxonase activity 
and increased lipid peroxidation levels in isolated HDL from 
obese adult patients,44 a decreased serum PON1 arylesterase 
activity was consistently reported in obese adults.45,46 Although 
data on PON1 paraoxonase activity in obesity revealed 
inconsistent findings with decrease in activity as shown in some 
studies,47,48 similar to our study no significant change was reported 
in the others.49–51
Enhanced platelet activity has been documented,3,54 in relation to 
the fact that abnormal platelet–endothelial interaction is an 
essential pathogenic mechanism in the development of 
atherosclerosis.52,53 Larger platelets are younger, more reactive, 
contain denser granules, and secrete more serotonin and 
β-thromboglobulin. They have been reported to produce more 
thromboxane A2 than smaller platelets. All these can produce a 
pro-coagulant effect and cause thrombotic vascular 
complications. This suggests a relationship between platelet 
function, especially with MPV and diabetic vascular complications, 
thus indicating changes in MPV and reflecting the state of 
thrombogenesis. High MPV has currently therefore emerged as a 
new risk factor for the vascular complications of DM.54–56
Significantly higher values for MPV in diabetic patients as opposed 
to non-diabetic subjects have consistently been reported in 
previous studies, with regard to an increased thrombotic 
state.3,29,30,57–59 Data from different cohorts of type 2 diabetes 
mellitus patients in Turkey revealed significantly higher values for 
MPV in diabetics compared with age- and sex-matched non-
diabetic healthy controls,29,60 and also in diabetics and subjects 
with impaired fasting glucose compared with the non-diabetic 
group, along with a positive correlation of MPV with HbA1c and 
fasting blood glucose (FBG) levels.60
Similarly, in another study from Turkey, MPV levels were reported 
to be significantly higher in type 2 diabetic patients with HbA1c 
levels > 7% than in patients with HbA1c levels ≤ 7% and in non-
diabetics,3 which is consistent with the statement that glycaemic 
control reduces MPV levels and hence the possible role of 
platelets in cardiovascular events observed in type 2 diabetic 
patients.61 Hyperglycaemia can increase platelet reactivity by 
Table 4: Correlation of mean platelet volume (MPV) values to brachial artery diameter and intima media thickness (IMT) in study groups
Note: Spearman correlation analysis. r: correlation coefficient.
Factor MPV values
Obesity Microvascular complications Macrovascular complications
(+) (−) (+) (−) (+) (−)
Brachial artery IMT
Right r −0.209 0.140 −0.011 −0.061 0.046 −0.063
p 0.150 0.318 0.952 0.610 0.771 0.634
Left r −0.232 0.114 −0.077 −0.064 0.012 −0.010
p 0.108 0.415 0.687 0.590 0.938 0.943
Brachial artery diameter
Right r −0.131 −0.042 −0.204 −0.084 −0.274 0.109
p 0.369 0.764 0.280 0.484 0.079 0.412
Left r −0.094 −0.068 −0.361 0.008 −0.205 0.054
p 0.522 0.627 0.050 0.944 0.193 0.685
45 Journal of Endocrinology, Metabolism and Diabetes of South Africa 2016; 21(3):40–46
9.  Beisswenger PJ, Drummond KS, Nelson RG, et al. 
Susceptibility to diabetic nephropathy is related to dicarbonyl 
and oxidative stress. Diabetes. 2005;54(11):3274–81. 
http://dx.doi.org/10.2337/diabetes.54.11.3274
10.  Bhatia S, Shukla R, Venkata Madhu S, et al Antioxidant status, lipid 
peroxidation and nitric oxide end products in patients of type 2 
diabetes mellitus with nephropathy. Clin Biochem. 2003;36(7):557–62. 
http://dx.doi.org/10.1016/S0009-9120(03)00094-8
11.  Canales A, Sánchez-Muniz FJ. Paraoxanase, something more 
than an enzyme? Med Clin (Barc). 2003;121(14):537–48. 
http://dx.doi.org/10.1016/S0025-7753(03)74011-1
12.  Durrington PN, Mackness B, Mackness MI. Paraoxonase and 
atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4):473–80 
http://dx.doi.org/10.1161/01.ATV.21.4.473
13.  Mackness MI, Arrol S, Durrington PN. Paraoxonase 
prevents accumulation of lipoperoxides in low-
density lipoprotein. FEBS Lett. 1991;286(1-2):152–4. 
http://dx.doi.org/10.1016/0014-5793(91)80962-3
14.  Mackness MI, Mackness B, Durrington PN, et al. 
Paraoxonase: biochemistry, genetics and relationship to 
plasma lipoproteins. Curr Opin Lipidol. 1996;7(2):69–76. 
http://dx.doi.org/10.1097/00041433-199604000-00004
15.  Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary 
heart disease: are activity and concentration more important 
than genotype? Arterioscler Thromb Vasc Biol. 2001;21(9):1451–7. 
http://dx.doi.org/10.1161/hq0901.094247
16.  Kota SK, Kota SK, Krishna SVS, et al. Implications of serum 
paraoxonase activity in obesity, diabetes mellitus, and 
dyslipidemia. Indian J Endocrinol Metab. 2013;17(3):402–12. 
http://dx.doi.org/10.4103/2230-8210.111618
17.  Goswami B, Tayal D, Gupta N, et al. Paraoxonase: a 
multifaceted biomolecule. Clin Chim Acta. 2009;410(1-2):1–12. 
http://dx.doi.org/10.1016/j.cca.2009.09.025
18.  Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from 
coronary heart disease in subjects with type 2 diabetes 
and in nondiabetic subjects with and without prior 
myocardial infarction. N Engl J Med. 1998;339(4):229–34. 
http://dx.doi.org/10.1056/NEJM199807233390404
19.  Nathan DM, Meigs J, Singer DE. The epidemiology of 
cardiovascular disease in type 2 diabetes mellitus: how 
sweet it is … or is it? Lancet. 1997;350(Suppl. 1):S4–S9. 
http://dx.doi.org/10.1016/S0140-6736(97)90021-0
20.  Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid 
intima-media thickness and risk of stroke and myocardial 
infarction: the Rotterdam study. Circulation. 1997;96(5):1432–7. 
http://dx.doi.org/10.1161/01.CIR.96.5.1432
21.  Stein JH, Fraizer MC, Aeschlimann SE, et al. Vascular age: 
integrating carotid intima-media thickness measurements with 
global coronary risk assessment. Clin Cardiol. 2004;27(7):388–92. 
http://dx.doi.org/10.1002/clc.4960270704
22.  Iwamoto Y, Maruhashi T, Fujii Y, et al. Intima-media thickness 
of brachial artery, vascular function, and cardiovascular risk 
factors. Arterioscler Thromb Vasc Biol. 2012;32(9):2295–303. 
http://dx.doi.org/10.1161/ATVBAHA.112.249680
23.  Vernekar PV, Vaidya KA. Comparison of mean platelet volume in type 2 
diabetics on insulin therapy and on oral hypoglycaemic agents. J Clin 
Diagn Res. 2013;7(12):2839–40.
24.  O’Malley T, Langhorne P, Elton RA, et al. Platelet 
size in stroke patients. Stroke. 1995;26(6):995–9. 
http://dx.doi.org/10.1161/01.STR.26.6.995
25.  Rao AK, Goldberg RE, Walsh PN. Platelet coagulant activities in diabetes 
mellitus. Evidence for relationship between platelet coagulant 
hyperactivity and platelet volume. J Lab Clin Med. 1984;103(1):82–92.
26.  Schultheiß HP, Tschoepe D, Esser J, et al. Large platelets 
continue to circulate in an activated state after 
myocardial infarction. Eur J Clin Invest. 1994;24(4):243–7. 
http://dx.doi.org/10.1111/j.1365-2362.1994.tb01081.x
27.  Gulcan AR, Karakaş MS, Akdemir B, et al. Relation between mean 
platelet volume and subclinical atherosclerosis in patients with 
metabolic syndrome. Turk Kardiyol Dern Ars. 2014 Jan;42(1):22–8. 
http://dx.doi.org/10.5543/tkda.2014.50708
expression or activity, along with the lack of data on other platelet 
volume indices, which may have varying associations with 
complications of vascular and peripheral neuropathy in type 2 
diabetes mellitus. Third, while drugs such as statins, fibrates, aspirin, 
glucocorticoids, and phenobarbital are amongst the classical 
inducers of PON1 activity16 and MPV values are significantly higher 
in diabetic patients receiving oral hypoglycaemic agents than in 
those patients on insulin therapy,23 no data have been collected on 
these treatments approaches. Lastly, study data were not analysed 
in subsets according to platelet size such as lower MPV, normal MPV 
or higher MPV, to investigate correlations with micro- and 
macrovascular complications. More detailed analysis could have 
revealed additional information about the MPV value and its 
possible correlations.
Accordingly, further larger-scale prospective studies with 
consideration of glycaemic control and anti-diabetic therapy, and 
the duration of diabetes would make a valuable contribution to 
the literature regarding the role of MPV as a prognostic marker of 
cardiovascular complications in diabetes mellitus.
In conclusion, our findings indicate a decreased PON1 activity 
and thus an increased atherosclerotic burden in diabetic patients 
with microvascular rather than macrovascular complications, No 
increase in thrombogenic activity along with no correlation of 
thrombogenic activity to PON-1 activity or BAd and BA-IMT was 
reported in diabetic patients regardless of obesity status or 
diabetic complications. Nonetheless, further larger-scale 
prospective case control studies are needed to draw a concrete 
conclusion regarding the role of MPV as a prognostic marker of 
cardiovascular complications in diabetes mellitus.
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